BridgeBio Pharma (BBIO) Share-based Compensation (2018 - 2026)

BridgeBio Pharma has disclosed Share-based Compensation across 9 years of filings, most recently posting $33.2 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $33.2 million, up 28.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $140.5 million (up 34.32% YoY), and the FY2025 annual result was $133.0 million, up 38.86% from the prior year.
• Share-based Compensation came in at $33.2 million for Q1 2026 at BridgeBio Pharma, down from $34.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $37.3 million in Q2 2025 to a low of $18.7 million in Q3 2022.
• The 5-year median for Share-based Compensation is $27.2 million (2023), against an average of $28.2 million.
• Across the five-year window, Share-based Compensation tumbled 30.42% in 2022 and soared 82.25% in 2023, its largest moves.
• BridgeBio Pharma's Share-based Compensation stood at $20.3 million in 2022, then surged by 82.25% to $37.0 million in 2023, then decreased by 18.63% to $30.1 million in 2024, then climbed by 14.98% to $34.6 million in 2025, then slipped by 4.03% to $33.2 million in 2026.
• The last three Share-based Compensation figures came in at $33.2 million (Q1 2026), $34.6 million (Q4 2025), and $35.3 million (Q3 2025), per Business Quant data.